Please login to the form below

Not currently logged in
Email:
Password:

Arena Pharmaceuticals

This page shows the latest Arena Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

Eisai agrees to pull obesity drug Belviq after safety alert

Eisai agrees to pull obesity drug Belviq after safety alert

In 2010, the FDA rejected the first marketing application for the drug, filed by its original developer, Arena Pharmaceuticals, asking for more details on cancer observed in animal studies. ... Belviq was never launched in Europe because Arena withdrew

Latest news

  • Eisai takes control of weight loss drug Belviq from Arena Eisai takes control of weight loss drug Belviq from Arena

    Frustrated with lacklustre sales growth, Eisai has bought global rights to weight-loss drug Belviq from its originator Arena Pharmaceuticals. ... Meanwhile, Arena says handing over rights means it can avoid around $80m in clinical development expenses.

  • US cuts at Boehringer hit sales force hardest US cuts at Boehringer hit sales force hardest

    And Arena Pharmaceuticals plans US and Swiss 'reductions'. Germany's Boehringer Ingelheim is to cut more than 700 jobs across its US operations, with the axe falling hardest on its sales ... Meanwhile Arena Pharmaceuticals is also slashing headcount at

  • Eisai adds online patient stories to Belviq marketing Eisai adds online patient stories to Belviq marketing

    PR Newswire. This is despite Eisai's development partner Arena Pharmaceuticals having registered the URL BelviqVoices.com earlier this year.

  • FDA approval for Novo Nordisk's obesity shot FDA approval for Novo Nordisk's obesity shot

    1999. In the last two years three other drugs have gained US marketing approval, including: Orexigen's Contrave, Vivus' Qsymia (phentermine/topiramate) and Arena Pharmaceuticals' Belviq (lorcaserin).

  • Orexigen’s obesity pill Mysimba set for European approval Orexigen’s obesity pill Mysimba set for European approval

    There are now four prescription medicines for obesity in the US, including Vivus' Qsymia (phentermine/topiramate) and Arena Pharmaceuticals' Belviq (lorcaserin), which were both approved in the last two years, alongside ... Arena had been seeking a

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    With a similar headline value to Synageva/Alexion and building on its acquisition plans was the purchase of Par Pharmaceuticals by Endo. ... 110. Arena Pharmaceuticals/ Roivant Sciences. Licence agreement. For Nelotanserin a 5-HT2A receptor P2 in

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Anthony Zook resigns as Vivus CEO Anthony Zook resigns as Vivus CEO

    This coup was led by investment group First Manhattan Co, which had attempted to replace the entire board of Vivus after Qsymia fell behind rival obesity drug Belviq (lorcaserin) from Arena ... Pharmaceuticals. Vivus also failed in a bid to win approval

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...
Six ways to improve diversity in clinical trials
Diversity is becoming increasingly important as a focus of clinical trials. This whitepaper gives six approaches that could be implemented to help make diversity a bigger focus on your clinical...